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Summary
A stepwise library-based strategy has been employed
to acquire a potent ligand for the SH3 domain of Fyn,
a Src kinase family member that plays a key role in T
cell activation. The easily automated methodology is
designed to identify potential interaction sites that
circumscribe the protein/peptide binding region on
the SH3 domain. The library protocol creates peptide/
nonpeptide chimeras that are able to bind to these
interaction sites that are otherwise inaccessible to
natural amino acid residues. The peptide-derived lead
and the Fyn-SH3 domain form a complex that exhibits
a KD of 25 ± 5 nM, approximately 1000-fold more po-
tent than that displayed by the corresponding con-
ventional peptide ligand. Furthermore, the lead ligand
exhibits selectivity against SH3 domains derived from
other Src kinases, in spite of a sequence identity of
approximately 80%.
Introduction
The Src homology 3 (SH3) domain is one of many pro-
tein recognition modules that play an essential role in
the operation of signaling pathways [1–3]. Like all pro-
tein recognition units, the SH3 domain exhibits a marked
preference for a particular consensus sequence of
amino acid residues, namely, a proline-rich motif of the
general form Pro-Xaa-Xaa-Pro [4]. The molecular basis
for the proline-based sequence preference has been re-
solved via the structural elucidation of several SH3 do-
main/peptide ligand complexes. The peptide ligand is
bound as a type II polyproline helix. Side chains on ev-
ery third residue of the helix are oriented in the same
direction. Two of these side chains are positioned into
hydrophobic pockets of the SH3 domain. In addition,
other residues of the peptide ligand are also able to
productively interact with the SH3 domain. One of the
interesting aspects of the polyproline helix structure is
that the ligand can associate with the binding pocket
in an N-to-C orientation or in the opposite sense [5].
The relative bound orientation is dictated by the pres-
ence of a positively charged residue on either the N
terminus of the peptide ligand (“Type I”) or at the corre-
sponding C terminus (“Type II”).
More than 400 different SH3 domains are encoded
within the human genome. Consequently, even at this
early stage in the analysis of the human proteome, it is
not surprising that these domains have been implicated
in a variety of normal and abnormal physiological pro-
cesses [6]. At the biochemical level, SH3 domains have*Correspondence: dlawrenc@aecom.yu.edubeen shown to regulate enzymatic activity as well as
promote the assembly of signaling complexes. For ex-
ample, all nine members of the Src family of protein
kinases contain the general structure (N terminus)-SH3-
SH2-SH1-(C terminus) [7]. The SH3 domain not only
serves as an intramolecular on/off switch that controls
kinase activity, but also acts as a targeting moiety that
directs Src kinase family members to the proper intra-
cellular sites and substrates. SH3 domains are present
in a variety of different proteins, including other tyrosine
kinases, such as Abl and Crk; protein phosphatases,
such as SHP-1; and adaptor proteins, such as Grb2
and Sos.
Many studies that seek to correlate the activity of a
given signaling protein with cellular phenotype typically
resort to the tools of molecular biology to create consti-
tutively active, dominant-negative, or other analogs of
the corresponding wild-type protein. Although this gen-
eral strategy is a powerful one, deletion of the natural
protein or expression of mutated analogs can result in
complications arising from compensation by closely re-
lated proteins, inappropriate localization of the protein
analog, or unintended modulation of other signaling
pathways. In contrast to genetically expressed protein
analogs, inhibitors or synthetic ligands rapidly perturb
the wild-type protein, which is present in its natural
state in terms of quantity, activity, and location. In this
regard, SH3 domain-selective ligands are a much sought-
after commodity. Unfortunately, the widespread pres-
ence of SH3 domains throughout the human proteome
and their generally similar ligand recognition profiles
renders this task a formidable one. In addition, several
studies have demonstrated that conventional peptide
ligands, consisting of standard amino acid (>10) resi-
dues, generally exhibit modest affinities (low M) and
low selectivities for their intended SH3 domain targets
[8–11]. Indeed, protein interaction domains, in general,
exhibit only moderately robust affinities for their endog-
enous ligands, a not too surprising observation given
the fact that the protein-protein interactions that drive
signaling cascades are transient by necessity.
We report, in this study, the synthesis and identifica-
tion of a peptide-derived ligand that selectively targets
the Fyn-SH3 domain. Fyn, a member of the Src tyrosine
protein kinase family, is known to play an important role
in the biochemical cascade responsible for T cell acti-
vation [12]. Both Fyn and its closely related counter-
part, Lck, exhibit similar substrate specificities, and the
SH2/SH3 domains of both proteins play key roles in
thymic development and T cell proliferation in response
to antigenic challenges. In particular, the SH3 domains
of both have been shown to interact with the Wiskott
Aldrich Syndrome protein (WASp) in vitro [13]. To the
best of our knowledge, this is the first report of a ligand
that is able to discriminate between SH3 domains of
the members of the Src kinase family.
Results and Discussion
The consensus sequences for a number of SH3 do-
mains have been reported. However, peptides (deca-
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906peptides and longer) bearing these sequences serve as
relatively modest SH3 domain ligands (M range). A
number of attempts have been made to enhance the
affinities of SH3 domain-directed peptides, either by
searching for optimized sequences via library methods
or by the introduction of nonnatural substituents at the
N or C termini [8–11]. However, these strategies typi-
cally do not furnish ligands that exhibit affinities signifi-
cantly beyond the M/nM border. By contrast, Lim and
his colleagues have demonstrated that N-substituted
peptides (“peptoids”) exhibit high affinities and good
selectivities for specific classes of SH3 domains [14,
15]. The critical design element in these studies is the
notion that N-substituted glycine residues serve as pro-
line mimetics and, given the diversity inherent within
the former, can be screened to identify substituents
that dramatically enhance SH3 domain affinity. Peptoid
ligands that exhibit nM affinities were identified for the
SH3 domains of Grb2 (N terminus; KD = 30 nM), Src
(KD = 140 nM), and Crk (KD = 8 nM) [14, 15]. Further-
more, these ligands exhibit a high selectivity in favor of
their targeted SH3 domain in spite of the fact that these
domains are structurally homologous (e.g., Crk and Src
SH3 domains display a 33% sequence similarity) [16].
These results dispel the previously held notion that it
is not possible to obtain tight binding ligands for SH3
domains due to the small size (60 amino acids).
We have previously described an iterative library-
based strategy that converts low-affinity consensus se-
quence peptides into high-affinity species that display
pronounced selectivities for their intended protein tar-
gets [17–20]. The methodology, as illustrated in general
form in Figure 1, has been successfully applied to SH2
domains, protein tyrosine phosphatases, and protein
kinases, including specific isoforms of the highly con-
served protein kinase C subfamily. However, the strat-
egy relies upon identifying a series of unique and widely
interspersed interaction sites on the protein surface.
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pFigure 1. Outline of the Iterative Library-
Based Strategy
The protocol seeks to identify potential in-
teraction sites that circumscribe the peptide
binding on the SH3 domain that are other-
wise inaccessible to conventional amino acid
residues. The final synthetic step, namely,
cleavage of the modified peptide from the
resin with assay buffer, delivers the library in
an assay-ready form.iven the small size of SH3 domains, it was far from
lear whether proteins of this size would be amenable
o such an approach. We decided to explore this ques-
ion by employing the SH3 domain of the Fyn tyrosine
inase as our target. Fyn is a member of the Src kinase
amily, a group of highly homologous tyrosine kinases.
he extremely high sequence homology displayed by
he SH3 domains from these proteins represents a seri-
us challenge in terms of acquiring selective inhibitors
e.g., the SH3 domains of Src and Fyn are 78% identical
21]). To the best of our knowledge, there are no exam-
les of ligands that distinguish between the SH3 do-
ains of the Src kinase family.
A good portion of the binding energy that drives SH3
omain/consensus sequence complex formation re-
ults from the interaction of key residues on the con-
ensus sequence peptide with hydrophobic pockets of
he SH3 domain. However, adjacent residues can also
ontribute binding energy by engaging in noncovalent
nteractions with subsites located proximal to these li-
ophilic pockets. The methodology described in Figure
allows one to screen for substituents positioned on
he peptide ligand that can engage in interactions with
he SH3 domain, which are simply not accessible to
aturally occurring amino acid residues. The consen-
us sequence peptide 1 was prepared on a disulfide-
inked Tentagel resin. One of the residues in 1 contains
L)-2,3-diaminopropionic acid 2 (Dap), which possesses
n amine handle on the side chain that can be readily
odified with an array of activated carboxylic acid moi-
ties. Peptide-resin 1 was then distributed, in equal
mounts, into individual wells of eight 96-well synthesis
lates. Each well was subsequently charged with a sin-
le carboxylic acid from a total library of 720 different
ommercially available carboxylic acids that vary in
ize, shape, polarity, and charge. Following acylation of
he amine moiety on Dap (3), the side chains of the
eptide were deprotected, and the peptide was subse-
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907quently cleaved from the resin (4) by using assay buffer
that contains dithiothreitol (DTT). The peptides were
then filtered from the synthesis plate into a receiving
plate and the 720-member library was subsequently
screened.
We employed Arg-Ala-Leu-Pro-Pro-Leu-Pro as the
starting point for Fyn-SH3 ligand optimization, and this
sequence is consistent with most known SH3 domain
binding elements. We initially introduced diversity ele-
ments on the N terminus of this peptide to furnish Li-
brary I (Figure 2). The 720 individual members of this
library were subsequently assessed for SH3 binding
potency via an ELISA-based screen. The latter was per-
formed in parallel by using strepavidin-coated 96-well
plates. A biotinylated peptide SH3-directed ligand was
appended to the individual wells, and a SH3 domain
GST fusion protein was subsequently introduced. Com-
petition between members of the library and the micro-
well bound biotinylated peptide ligand determined the
extent to which the SH3 domain GST fusion protein was
retained by the individual wells after washing. The latter
was quantified by using an anti-GST-peroxidase fusion
construct. The assay is dependent upon a strong bind-
ing interaction between the SH3 domain GST fusion
protein and the biotinylated peptide ligand associated
with the strepavidin-coated well. Unfortunately, as noted
above, conventional peptide ligands bind modestly to
SH3 domains. Consequently, we decided to prepare,
for screening purposes, a variant of the peptoid series
reported by Lim and his colleagues [14, 15]. Although
the 13 residue-containing peptoid 5 does not discrimi-
nate between the SH3 domains of Src, and Grb2, it
does exhibit a moderately good affinity for these do-
mains (KD = w150 nM). We prepared construct 6, which
contains an aminohexanoic acid (Ahx) dyad between
the biotin substituent and the N-benzylated consensus
sequence (Figure 3). The Ahx2 linker serves to ensure
that the SH3 domain has spatial access to the micro-
well bound peptoid moiety. We also prepared the fluo-
rescein-labeled analog 7, which exhibits a K of 230 ±Figure 2. Preparation of Libraries I–V
In Libraries I–V, a = Pd, b = 3% CF3CO2H, c =
720 RCO2H, and d = assay buffer contain-
ing dithiothreitol.Dwith respect to the SH3 domains from Lck and Hck.
Figure 3. Peptoides 5, 6, and 7
Peptoid 6, which was based on the previously described peptoid 5
[15], was used for the ELISA screen. The fluorescently labeled pep-
toid 7 exhibits a K of 230 ± 30 nM for the Fyn-SH3 domain.30 nM for the Fyn-SH3 domain, but with little selectivity
versus other members of the Src kinase family (vide
infra and Table 1).
Our initial screen of the heptapeptide-based Library
I revealed three lead derivatives. These leads were re-
synthesized on the Rink resin as the C-terminal amide-
capped derivatives (compounds 8a–8c; Figure 4), puri-
fied, and their IC50 values subsequently determined by
using the ELISA assay described in the previous para-
graph. Their relative affinities ranged from 15 M for
the 2-hydroxynicotinic acid derivative 8a up to 45 M
for the cyclopropyl derivative 8c. KD values were ob-
tained via equilibrium dialysis by using the fluorescent
intensity inherent within the nicotinic acid moiety. The
KD for the lead derivative from Library I, compound 8a,
is 1.2 ± 0.2 M, a nearly 15-fold improvement relative
to the corresponding acetylated derivative 9 (KD = 15 ±
4 M). As expected, the parent peptide 9 is unable to
discriminate between the various SH3 domains of the
Src family members (Table 1). By contrast, some selec-
tivity in favor of Fyn is apparent with 8a, particularlyD
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908Table 1. Dissociation Constants of Ligands for Various Src Family SH3 Domains
Ligand Fyn Lck Src Yes Hck
7 0.23 ± 0.03 0.29 ± 0.05 0.21 ± 0.04 N/A N/A
8a 1.2 ± 0.2 5.3 ± 0.4 2.5 ± 0.2 2.7 ± 0.3 5.1 ± 0.7
9 15 ± 4 19 ± 8 21 ± 4 17 ± 6 31 ± 8
11a 0.11 ± 0.03 0.59 ± 0.08 0.37 ± 0.05 0.38 ± 0.14 0.62 ± 0.07
14 0.025 ± 0.005 0.27 ± 0.03 0.23 ± 0.04 0.19 ± 0.02 0.26 ± 0.03
Dissociation constants are given in M.work, the Adpoc protecting group on the Dap side
Figure 4. Leads Derived from Libraries I–V
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the SH3 domains of Fyn, Yes, and Src. Although the
molecular basis for this emerging selectivity remains to
be resolved, we do note that, on the basis of sequence
identity, Lck and Hck (Group B Src kinases) lie on a
separate branch of the evolutionary tree from Fyn, Yes,
and Src (Group A Src kinases) [22]. This might account
for the modest selectivity that compound 8a exhibits
for the Fyn-SH3 domain versus those from Lck and
Hck.
With a biasing element at the N terminus of Arg-Ala-
Leu-Pro-Pro-Leu-Pro in place, we subsequently exam-
ined the effect of nonnatural substituents at various
internal sites of the consensus sequence peptide. Spe-
cifically, three sublibraries of the peptide 8a lead con-
taining Dap replacements at Leu-3 (Library II), Leu-6
(Library III), and at the C terminus (Library IV) were pre-
pared. These libraries were prepared as depicted in
Figure 2. In all three cases (10a–10c), the Dap-contain-
ing 2-hydroxynicotinic acid-derivatized peptides were
synthesized via an Fmoc protocol on the disulfide Ten-
tagel resin. Following completion of the peptide frame-
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dhain was selectively removed under mildly acidic
onditions, the peptide-resin distributed to individual
icrowells, and the Dap amino group subsequently
cylated with 720 different carboxylic acid derivatives
Libraries II–IV). As with Library I, each of the three
ublibraries contained 720 distinct and physically sepa-
ate members. The 2160 compounds that constitute Li-
raries II–IV were screened by using the ELISA assay
escribed above. The lead compounds from this
creen were obtained exclusively from Library IV. These
ompounds were resynthesized on the Rink resin as
he C-terminal amide-capped derivatives (11a–11d, Fig-
re 4), purified, and subsequently assessed for Fyn-
H3 affinity. Compound 11a exhibits a KD of 110 ± 30
M, more than a 100-fold enhancement in affinity rela-
ive to the parent compound 9 (Table 1). In addition, a
light improvement in selectivity for the Fyn-SH3 do-
ain relative to Lck and Hck is apparent, as is the
mergence of discriminatory behavior versus that of
es and Src.
Based on the optimized sequence contained in 11a,
e prepared a second sublibrary containing molecular
iversity introduced at the Ala-2 position. Library V con-
ains two Dap residues, each of which must be selec-
ively modified. A number of synthetic strategies are
ossible. However, given the possible reactivity of the
atechol hydroxyl moieties of the Dap substituent in
1a, we decided to introduce the 2,3-dihydroxybenzoic
cid moiety after completion of the peptide framework
Figure 2). This required the use of two different Dap
esidues that were differentially side chain protected.
he peptide-Tentagel resin 12 was prepared via Fmoc
hemistry. The Adpoc group on the C-terminal Dap resi-
ue was selectively removed with 3% CF3CO2H, and
,3-dihydroxybenzoic acid was subsequently coupled
o the free amine side chain (13). The Alloc-protected
ap moiety at position 2 was then removed with PdO,
nd the resultant peptide-resin containing the free
mine was distributed in equal amounts to 720 indi-
idual microwells for coupling with activated carboxylic
cids (Library V). The peptide library was then side
hain deprotected, extensively washed, and subse-
uently released from the Tentagel resin by using assay
uffer. Screening of Library V furnished a single lead
ompound, which was resynthesized, purified, and
valuated as a ligand (14) for the SH3 domain of Fyn.
s depicted in Table 1, peptide 14 displays a KD of 25 ±
nM for the SH3 domain of Fyn, a nearly 1,000-fold
nhanced affinity relative to the starting parent peptide
. In addition, the former exhibits a 10-fold selective
ffinity for Fyn versus SH3 domains from other Src ki-
ase family members. To the best of our knowledge,
his is the first example of a ligand that is able to distin-
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909guish between the SH3 domains of this closely related
group of protein kinases.
As noted in the Introduction, Fyn is known to play an
important role in mediating the activation and prolifera-
tion of T cells via a signaling pathway that emanates
from the T cell receptor. Recent studies have demon-
strated that WASp is a participant in this pathway by
directly interacting with and undergoing phosphoryla-
tion by Fyn [13, 23]. The association of a proline-rich
region on WASp with the SH3 domain of Fyn drives the
formation of the transient WASp/Fyn complex. Fyn-
mediated WASp phosphorylation at Tyr-291 releases
WASp from an autoinhibitory conformation. Upon acti-
vation, WASp induces Arp2/3 activity, which, in turn,
promotes actin polymerization. In an apparently analo-
gous fashion, the B cell lineage Src kinase, Hck, like-
wise interacts with WASp in an SH3 domain-dependent
manner [24]. For our initial studies, we examined the
ability of compound 14 to block the interaction of
WASp with the Fyn-SH3 domain. We employed the hu-
man leukemia monocyte U937 cell line that was pre-
viously used to identify WASp as a Fyn-SH3 domain
interacting protein [13]. Lysates from both undifferenti-
ated U937 cells and phorbol 12-myristate 13-acetate-
treated cells were employed [25]. Both protocols fur-
nished similar results. The lysates were separately
added to a mixture of glutathione-sepharose beads
saturated with Fyn-SH3 GST fusion protein and varied
amounts of Fyn-SH3 ligand 14 or the corresponding
acetylated parent peptide 9. The sepharose beads were
collected, the bound proteins released and fractionated
by SDS-PAGE, and WASp visualized via chemilumines-
cence with an anti-WASp monoclonal antibody. As is
evident from Figure 5, ligand 14 disrupts formation of
the WASp/Fyn complex with a greater than 100-fold en-
hanced potency relative to peptide 9.
Conclusions
We have acquired a Fyn-SH3 domain-selective ligand
via an iterative library-based approach. This strategy
relies on the identification of widely distributed interac-
tion sites on the surface of the target protein. Our re-
sults demonstrate that, even for a protein as small as
an SH3 domain, potent ligands can be prepared by
using the stepwise protocol outlined in Figure 1. To the
best of our knowledge, ligand 14 displays the highest
affinity ever reported for an SH3 domain from the SrcFigure 5. Inhibition of WASp/Fyn-SH3 Interaction with the Fyn SH3
Domain Ligand 14
Glutathione sepharose beads saturated with Fyn SH3 were incu-
bated with U937 cell lysates in the presence of inhibitory peptide
14 or acetylated control 9 at the appropriate concentrations (M).kinase family. Furthermore, we have observed for the
first time the emergence of a ligand that distinguishes
between the SH3 domains (w80% sequence identity)
of the highly conserved Src family of proteins. Clearly,
it would be extremely useful to have an assortment of
relatively low-molecular weight ligands that selectively
target individual members of the Src kinase family.
These studies are in progress, as is an examination of
the molecular basis for the potency and selectivity as-
sociated with ligand 14.
Significance
Signal transduction is primarily driven by protein-pro-
tein interactions. Given the important role that cell
signaling plays in both normal and abnormal cellular
events, there has been intense interest in the acqui-
sition of inhibitory agents that block signaling path-
ways by interfering with the ability of proteins to
recognize their appropriate binding partners. SH3 do-
mains are amongst the smallest of all known protein
binding modules and thus represent a significant
challenge in terms of acquiring high-affinity ligands.
We have developed a straightforward stepwise strat-
egy that has furnished an extremely potent ligand for
the Fyn-SH3 domain. The latter exhibits a sequence
identity of 80% with other SH3 domains from the Src
family of protein kinases. The Fyn ligand identified
in this study represents the first example of a small
nonprotein molecule that is able to distinguish
amongst the Src SH3 domain proteins.
Experimental Procedures
The resins and reagents used for solid phase peptide synthesis,
including Tentagel resin, Rink resin, N-9-fluorenylmethyloxycarbonyl
(Fmoc)-L-amino acids, N,N,N#,N#-tetramethyl-(succinimido)uranium
tetrafluoroborate (TSTU), benzotriazole-1-yloxytrispyrrolidinophos-
phonium hexafluorophosphate (PyBOP), 1-hydroxybenzotriazole
(HOBt), were purchased from Advanced ChemTech. Peptide syn-
thesis grade dichloromethane (DCM), N,N-diisopropylethylamine
(DIPEA), isopropyl alcohol (IPA), dimethylformamide (DMF), and tri-
fluoroacetic acid (TFA) were purchased from Fisher, and piperidine
was obtained from Lancaster. 2-Fmoc-3-[1-(1#-Adamantyl)-1-methyl-
ethoxycarbonyl]-diaminopropionic acid (Fmoc-Dap(Adpoc)-OH) was
obtained from Bachem. Triisopropylsilane (TIS) was purchased
from Acros. The 720 carboxylic acids used for the preparation of
the peptide libraries were purchased from Aldrich. The SH3 domain
GST fusion proteins, Fyn (85–139) and Lck (54–120), and polyclonal
rabbit anti-GST HRP conjugate antibody were purchased from
Santa Cruz Biotechnology. Peroxidase substrate (1-step Turbo tri-
methylbenzidine ELISA), streptavidin-coated 96-well plates, and
Slide-A-Lyzer dialysis slide cassettes (Mr 10,000 cutoff) were pur-
chased from Pierce. Solvent-resistant MultiScreen 96-well filter
plates and the MultiScreen 96-well filter plate vacuum manifold
were purchased from Millipore Corp.
One-dimesional and two-dimensional 1H NMR spectra of the
peptide inhibitors were recorded on a DRx600 MHz Spectrometer
in H2O/D2O (90:10), and chemical shifts are reported in parts per
million (ppm) downfield from (CH3)4Si. The molecular weights of
the peptides were analyzed with MALDI mass spectrometry on an
Applied Biosystems Voyager DE STR and ESI-MS on an Applied
Biosystems MDS SCIEX API Qstar Pulsar I. Reverse-phase high-
performance liquid chromatography (RP-HPLC) was performed on
a Waters SD-200 solvent delivery system equipped with a 500 UV/
Vis-absorbance detector and recorded on an Apple Macintosh
computer with model 600 software (Applied Biosystems, Inc.).
Chromatographic separations were achieved by using linear gradi-
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910ents of buffer B in A (A = 0.1% aqueous TFA; B = 0.1% TFA in
CH3CN) over 50 min at a flow rate of 12 ml/min with a detection
wavelength of 218 nm on Delta-Pak C18 (300 Å, 15 m, 3 × 15
cm) column.
Peptide Synthesis
Peptides were synthesized by using a standard Fmoc solid phase
peptide synthesis (SPPS) protocol on an Innova 2000 platform
shaker, or with an Advanced Chemtech Model 90 Tabletop Pep-
tide Synthesizer.
Synthesis of Library I
A total of 5 g Tentagel S COOH (90 m, 0.2 mmol/g) and 1.94 g (15
mmol) DIPEA were successively added to a solution of 1.5 g (5
mmol) TSTU in 20 ml DMF. The mixture was shaken for 2 hr at
ambient temperature. Subsequently, a mixture of 2.25 g (10 mmol)
cystamine dihydrochloride and 2.02 g (20 mmol) N-methylmorpho-
line (NMM) in 20 ml water was slowly added to the Tentagel reac-
tion mixture. Heat was evolved upon addition. Upon cooling to
room temperature, the reaction vessel was sealed and shaken
overnight. The resin was then drained and washed successively
with H2O (3 × 20 ml), DMF (3 × 20 ml), and CH2Cl2 (3 × 20 ml). The
free amine substitution level on linker-coupled resin was found to
be 0.05 mmol/g. The linker-coupled resin (5 g) was successively
submitted to coupling reactions with the required amino acids, fol-
lowed by removal of the Fmoc protecting group via standard condi-
tions (vide infra). Each residue was coupled for 3 hr, and coupling
efficiencies were determined by a quantitative ninhydrin reaction.
The standard coupling conditions employed 5 equiv. of Fmoc
amino acid, 5 equiv. of HOBt, 5 equiv. of PyBOP, and 10 equiv. of
NMM in 30 ml DMF with shaking for 3 hr. After each coupling step,
the resin was successively washed with DMF (3 × 20 ml), IPA (3 ×
20 ml), and CH2Cl2 (3 × 20 ml). The Fmoc protecting group was
removed with 20% piperidine in DMF (shaking for 20 min). After the
assembly of the consensus sequence of Fmoc-Arg(Pbf)-Ala-Leu-
Pro-Pro-Leu-Pro-S-S-Tentagel-Resin, the Fmoc group at the amino
terminus was removed, and the resin was extensively washed and
subsequently dried in vacuo. The peptide bound resin was distrib-
uted in 5 mg quantities into individual wells of solvent-resistant
MultiScreenTM 96-well filter plates (8 plates total). To each well
was added a solution of a carboxylic acid (200 equiv.) in 100 l
DMF and a second solution containing PyBOP (200 equiv.), HOBt
(200 equiv.), and NMM (400 equiv.) in 100 l DMF. A total of 720
different carboxylic acids were employed. The plates were gently
shaken overnight, and then each well was subjected to a series of
washing steps (3 × 200 l DMF, 3 × 200 l IPA, and 3 × 200 l
CH2Cl2). The side chain protecting group Pbf was removed via
treatment with TFA:H2O:TIS (v/v 95:2.5:2.5) for 2 × 3 hr at ambient
temperature. The resin was washed with DMF (3 × 20 ml), IPA (3 ×
20 ml), and CH2Cl2 (3 × 20 ml), and the peptide/nonpeptide conju-
gates were subsequently cleaved from the disulfide-containing
resin with 10 mM dithiothreitol (DTT) in 50 mM Tris ( pH 7.5) (1 ×
200 l for 3 hr and 2 × 150 l for 3 hr each) and filtered into a
receiving set of 96-well plates by using a vacuum manifold (final
volume of 500 l). The coupling efficiency of the acylation reaction
and the purity of peptide/nonpeptide conjugates were assessed via
the ninhydrin test and RP-HPLC, respectively. No free N-terminal
peptide was detected, and >90% of total ligand was cleaved from
the resin with the first DTT cleaving step. The final two DTT wash-
ings removed the residual resin bound peptide. Compound purity
was >90%, as assessed by HPLC, and the HPLC-purified com-
pounds (i.e., removal of Tris buffer and DTT) were characterized by
MALDI-MS. These peptides, containing 720 different groups at the
N terminus of consensus sequence in 8 plates, comprise Library I.
Synthesis of Libraries II, III, and IV
Construction of Libraries II, III, and IV is depicted in Figure 2. The
side chain-protected consensus sequence Fmoc-Arg(Pbf)-Ala-Leu-
Pro-Pro-Leu-Pro-S-S-Tentagel-Resin was assembled on the Tentagel
resin as described in the previous paragraph with the following sub-
stitutions: the N terminus leucine was replaced with a Dap(Adpoc)-
OH to afford Library II, the C terminus leucine was replaced with a
Dap(Adpoc)-OH to afford Library III, a Dap(Adpoc)-OH residue was
inserted into the C terminus of the sequence to afford Library IV.
The N terminus Fmoc group (5 g resin) was then removed with 20%
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(iperidine in DMF, and the resin was thoroughly washed with DMF,
PA, and CH2Cl2. A solution containing 2-hydroxynicotinic acid (695.5
g, 8 equiv.), PyBOP (2.6 g, 8 equiv.), HOBt (765 mg, 8 equiv.), and
MM (1.26 g, 20 equiv.) in 30 ml DMF was added, and the slurry
as shaken overnight at room temperature. The solvent was re-
oved from the resin, and the resin was subsequently washed with
MF (3 × 20 ml), IPA (3 × 20 ml), and CH2Cl2 (3 × 20 ml). The Adpoc
roup in these three sequences (5 g resin) was selectively removed
ith 40 ml 3% TFA in CH2Cl2 (3 × 5 min), and the resin bearing free
mine on the Dap residue was washed, dried, and then added in
mg quantities to the individual wells of eight solvent-resistant
ultiScreenTM 96-well filter plates. The following procedures, as
escribed for Library I, were employed: the resin in each well was
oupled with 1 of 720 different carboxylic acids, the side chain
rotecting groups were removed, and the peptides were cleaved
rom the resin to furnish Libraries II, III, and IV.
ynthesis of Library V
onstruction of Library V was depicted in Figure 2. The side chain-
rotected consensus sequence Fmoc-Arg(Pbf)-Dap(Alloc)-Leu-
ro-Pro-Leu-Pro-Dap(Adpoc)-S-S-Tentagel-Resin was assembled
n the Tentagel resin as previously described. The N terminus
moc group (5 g resin) was removed with 20% piperidine in DMF,
nd the resin was washed and coupled to 2-hydroxynicotinic acid
n the same fashion described in the previous paragraph. The Ad-
oc group in the sequence (5 g resin) was selectively removed with
0 ml 3% TFA in CH2Cl2 (3 × 5 min), and the resulting free amine
n the side chain of the Dap residue was coupled with 770 mg (5
mol) 2,3-dihydroxybenzoic acid in the presence of 1.9 g (5 mmol)
ATU, 0.765 g (5 mmol) HOAt, and 1.29 g (10 mmol) DIPEA in 40
l DMF. The reaction mixture was shaken overnight at room tem-
erature. After the solvent was removed and the resin was subse-
uently washed, a solution of 58 mg (0.05 mmol, 0.2 equiv.)
d(PPh3)4 in 30 ml solvent of THF:DMSO:(0.5 M HCl):morpholine
v/v 20:20:10:1) was added to the resin and shaken for 24 hr at
oom temperature [26] to selectively deprotect the Alloc group pro-
ecting the N terminus Dap residue. The doubly modified peptide
esin of (2-hydroxynicotinic)-HN-Arg(Pbf)-Dap-(NH2)-Leu-Pro-Pro-
eu-Pro-Dap-(NH-2,3-dihydroxybenzoic)-Phe-S-S-Tentagel-Resin
t this stage was thoroughly washed, dried in vacuum, and added
n 5 mg quantities to the individual wells of eight solvent-resistant
ultiScreenTM 96-well filter plates. The resin in each well was then
oupled with 1 of 720 different carboxylic acids, the side chain
rotecting groups were removed, and the peptides were cleaved
rom the resin to furnish Library V.
Peptide 8a. The peptide-resin Fmoc-Arg(Pbf)-Ala-Leu-Pro-Pro-
eu-Pro-NH-Rink-resin was prepared by using the protocol de-
cribed above for Library I, but by using the Rink SS resin instead
f TentaGel S COOH. After the Fmoc group was removed on the N
erminus and the resin was thoroughly washed, a solution contain-
ng 2-hydroxynicotinic acid (5 equiv.), PyBOP (5 equiv.), HOBt (5
quiv.), and NMM (15 equiv.) in DMF was added, and the slurry
as shaken overnight at room temperature to afford the peptide
odified at the N terminus. The peptide was subsequently depro-
ected and released from the resin in one step by using a TFA/TIS/
2O (v/v 95:2.5:2.5) cocktail for 2–3 hr. ESIMS m/z calculated for
42H65N11O10 884.03 (MH+), Found m/z 884.8.
Peptide 11a. The peptide-resin (2-hydroxynicotinic-NH)-Arg(Pbf)-
la-Leu-Pro-Pro-Leu-Pro-Dap(Adpoc)-NH-Rink-resin was prepared
y using the protocol described above for Library IV, but by using
ink SS resin instead of TentaGel S COOH. After Adpoc deprotec-
ion with 3% TFA in DCM and resin washing, a solution of 2,3-
ihydroxybenzoic acid (5 equiv.), HATU (5 equiv.), HOAt (5 equiv.),
nd DIPEA (10 equiv.) in DMF was added, and the slurry was
haken for 3 hr at room temperature to afford the peptide modified
t the C terminus. The peptide was subsequently deprotected and
eleased from the resin in one step by using a TFA/TIS/H2O (v/v
5:2.5:2.5) cocktail for 2–3 hr. 1H NMR (600 MHz, H2O, ppm) 7.81
1H), 6.75 (1H), 8.49 (1H) for N terminus nicotinic acid aromatic
ydrogens; 10.31 (1H, s, CONH), 4.55 (1H, CαH), 1.95 (1H, CβH), 1.88
1H, CβH), 1.69 (2H, CγH2), 3.23 (2H, CδH2), 7.24 (NH) for Arg-1; 8.58
1H, s, CONH), 4.37 (1H, CαH), 1.38 (2H, CβH2) for Ala-2; 8.31 (1H, s,
ONH), 4.62 (1H, CαH), 1.56 (2H, CβH2), 1.67 (2H, CγH2), 0.91 (2H,
δH2) for Leu-3; 4.70 (1H, CαH), 2.34 (1H, CβH), 1.90 (1H, CβH), 2.03
2H, C H ), 3.83 (1H, C H), 3.67 (1H, C H) for Pro-4; 4.42 (1H, C H),γ 2 δ δ α
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9112.27 (1H, CβH), 1.90 (1H, CβH), 2.03 (2H, CγH2), 3.79 (1H, CδH), 3.65
(1H, CδH) for Pro-5; 8.16 (1H, s, CONH), 4.57 (1H, CαH), 1.45 (2H,
CβH2), 1.65 (2H, CγH2), 0.86 (2H, CδH2) for Leu-6; 4.39 (1H, CαH),
2.27 (1H, CβH), 1.90 (1H, CβH), 2.03 (2H, CγH2), 3.84 (1H, CδH), 3.66
(1H, CδH) for Pro-7; 8.34 (1H, s, CONH), 4.66 (1H, CαH), 3.86 (1H,
CβH), 3.77 (1H, CβH), 7.61 (amide NH of C terminus), 7.25 (amide
NH of C terminus) for Dap-8; 8.74 (1H, s, CONH); 7.10 (1H), 6.88
(1H), 7.25 (1H) for C terminus 2,3-dihydroxyl benzoic acid. ESIMS
m/z calculated for C52H76N14O13 1105.25 (MH+), Found m/z 1104.6.
Peptide 14. The peptide-resin (2-hydroxynicotinic-NH)-Arg(Pbf)-
Dap(alloc)-Leu-Pro-Pro-Leu-Pro-Dap(NH-2,3-dihydroxybenzoic)-
NH-Rink-resin was prepared by using the protocol described
above for Library V using Rink SS resin. After alloc deprotection
with Pd(0) and resin washing, a solution of (R)-(-)-Mandelic acid (5
equiv.), PyBOP (5 equiv.), HOBt (5 equiv.), and NMM (15 equiv.) in
DMF was added, and the slurry was shaken for 3 hr at room tem-
perature to afford the second Dap residue modification. The pep-
tide was subsequently released from the resin in one step by using
a TFA/TIS/H2O (v/v 95:2.5:2.5) cocktail for 2–3 hr. 1H NMR (600
MHz, H2O, ppm) 7.78 (1H), 6.70 (1H), 8.32 (1H) for N terminus nico-
tinic acid aromatic hydrogens; 10.30 (1H, s, CONH), 4.48 (1H, CαH),
1.88 (1H, CβH), 1.80 (1H, CβH), 1.65 (2H, CγH2), 3.17 (2H, CδH2), 7.19
(NH) for Arg-1; 8.57 (1H, s, CONH), 4.60 (1H, CαH), 3.82 (1H, CβH),
3.57 (1H, CβH) 8.49 (CONH, s, CONH of Dap-2-hydroxyl benzoic
acid) for Dap-2; 8.40 (1H, s, CONH), 4.62 (1H, CαH), 1.59 (2H, CβH2),
1.64 (2H, CγH2), 0.90 (2H, CδH2) for Leu-3; 4.65 (1H, CαH), 2.32 (1H,
CβH), 1.89 (1H, CβH), 2.04 (2H, CγH2), 3.86 (1H, CδH), 3.62 (1H, CδH)
for Pro-4; 4.42 (1H, CαH), 2.27 (1H, CβH), 1.89 (1H, CβH), 2.0 (2H,
CγH2), 3.73 (1H, CδH), 3.60 (1H, CδH) for Pro-5; 8.15 (1H, s, CONH),
4.57 (1H, CαH), 1.45 (2H, CβH2), 1.64 (2H, CγH2), 0.85 (2H, CδH2) for
Leu-6; 4.42 (1H, CαH), 2.27 (1H, CβH), 1.89 (1H, CβH), 2.0 (2H, CγH2),
3.82 (1H, CδH), 3.65 (1H, CδH) for Pro-7; 8.34 (1H, s, CONH), 4.64
(1H, CαH), 3.86 (1H, CβH), 3.76 (1H, CβH), for Dap-8; 8.73 (1H, s,
CONH); 7.09 (1H), 6.87 (1H), 7.22 (1H) for C terminus 2,3-dihydroxyl
benzoic acid. ESIMS m/z calculated for C60H82N14O16 1255.38
(MH+), Found m/z 1255.9.
Synthesis of Peptoid Ligands 5–7
Peptoid ligands 5–7 were synthesized on the Rink resin by using a
standard solid phase peptide synthesis protocol with the following
exception to introduce the N-glycine-substituted peptoid moiety:
after the assembly of the Pro-Arg-Asn-Arg-Pro-Arg-Ala sequence
on the Rink resin, the N terminus of the peptide was acylated by
reaction with equal volumes of 1 M bromoacetic acid in DCM (10
equiv.) and 1 M diisocarbodiimide in DMF (10 equiv.) twice for 1
hr each; nucleophilic displacement was effected with 2 M N-(S)-
phenylethyl amine in dimethyl sulfoxide (15 molar equiv.) twice for
2 hr each. The subsequent Fmoc amino acid (10 equiv.) was ap-
pended by using the coupling reagent HATU (10 equiv.) and DIPEA
(18 equiv., twice for 2 hr each). Two Fmoc-Aminohexanoic acid
(Fmoc-Ahx) residues were coupled to the N terminus as spacers
between the peptoid ligand and the appended moiety (biotin, 6;
fluorescein, 7). Biotinylation was effected on the resin with 4 equiv.
of biotin in DMSO/DMF (v/v 50:50) in the presence of coupling rea-
gents (PyBOP, 4 equiv.; HOBt, 4 equiv.; NMM, 4 equiv.) at room
temperature for 3 hr. FITC labeling was likewise conducted on the
resin with 2 equiv. of FITC dissolved in pyridine/DMF/DCM (v/v
12:7:5) at room temperature in the dark overnight. Peptoid ligands
5–7 were subsequently deprotected and released from the Rink
resin by using a TFA/TIS/H2O cocktail (v/v 95:2.5:2.5) for 3 hr.
ESIMS of 6 calculated for C96H150N26O20S m/z 2020.45 (MH+),
Found m/z 2020.78. ESIMS of 7 calculated for C107H147N25O23S
m/z 2183.53 (MH+), Found m/z 2184.13.
Screening of the Peptide/Nonpeptide Conjugate Library
An ELISA assay was employed to screen the library for SH3 affinity.
A total of 100 l biotinyl-(-aminocaproyl)2-Tyr-Ala-Pro-Pro-Leu-[N-
(S)-phenylethyl]Gly-Pro-Arg-Asn-Arg-Pro-Arg-Ala-amide 6 (333 ng/
ml in 50 mM Tris, 150 mM NaCl [pH 7.5]) was added to each well
of streptavidin-coated 96-well microtiter plates. The plates were
shaken overnight at 4°C and rinsed with TBS (50 mM Tris, 150 mM
NaCl [pH 7.5], 3 × 200 l). Each well was then blocked with 100 l
of a solution containing 2% BSA and 0.2% Tween 20 in TBS (2 hrat room temperature). The wells were rinsed with 4 × 200 l of a
standard “BSA-T-TBS” solution (0.2% BSA, 0.1% Tween 20, TBS).
A 50 l solution of the peptide/nonpeptide conjugate (100 nM, in
BSA-T-TBS) from the library and a 50 l solution of the Fyn-SH3
GST fusion protein (32 ng/ml, in BSA-T-TBS) were added in each
well, and the plate was shaken for 2.5 hr at room temperature. The
solutions were removed, and each well was rinsed with 4 × 200 l
BSA-T-TBS. 100 l of horse radish peroxidase-conjugated rabbit
polyclonal anti-GST antibody (100 ng/ml in BSA-T-TBS) was then
added to each well and incubated for 2 hr at room temperatrure.
After a series of final wash steps (4 × 200 l BSA-T-TBS; 4 × 250
l TBS), 100 l peroxidase substrate (1-step Turbo TMB-ELISA,
trimethylbenzidine) was added to each well and incubated for 5–15
min. A total of 100 l 1 M sulfuric acid solution was introduced to
stop the peroxidase reaction, and absorbance was measured at
450 nm with a plate reader. IC50 values were determined by using
the ELISA screening method around a 200-fold range of ligand con-
centrations.
WASp/Fyn Binding Assay
U937 cells were maintained in RPMI 1640 medium supplemented
with 5% fetal bovine serum. To induce differentiation toward a
monocytic lineage, exponentially growing U937 cells were subcul-
tured at a density of 5 × 105 cells ml−1 and treated with PMA
(Sigma) at a final concentration of 10 ng ml−1 for 24 hr. Cells were
then harvested and washed in ice-cold phosphate-buffer saline
and lysed in 10 mM Tris-HCl (pH 7.5), 1% (v/v) Triton X-100, 150
mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM phenylmethylsulfonyl
chloride, 5 mM benzamidine, 1 mM NaVO4, and protease inhibitors
(5 g/ml aprotinin, 5 mg/ml leupeptin, 5 g/ml pepstatin). Protein
concentrations were measured by using the Bradford assay after
preclearing the lysate with glutathione-sepharose beads. Aliquots
of cell lysate were added to 20 l glutathione-sepharose beads
saturated with Fyn-SH3 GST fusion protein in the presence of pep-
tide 14 or acetylated control 9. Beads and lysate were gently
shaken for 2 hr at 4°C and then washed five times with lysis buffer.
Bound proteins were eluted into gel loading buffer by boiling, were
fractionated by SDS-PAGE under reducing conditions, and were
then electrotransferred to polyvinylidene difluoride (PVDF) mem-
branes (Millipore). The membranes were blocked via overnight ex-
posure to PBS buffer with 5% nonfat milk. The amount of WASp
associated with Fyn SH3 was detected by sequential incubation
with anti-WASp monoclonal antibody (Pharmingen, CA) and sec-
ondary HRP-conjugated antibody (Pharmingen, CA), and were then
visualized with an enhanced chemiluminescent (ECL) Western blot-
ting reagent according to the manufacturer’s instructions (Amer-
sham). The same PVDF membrane was stripped in 0.2 N NaOH
solution for 10 min and was blotted against anti-GST HRP antibody
(Santa Cruz Biotech, CA) to verify that an equal amount of Fyn SH3
protein was loaded into each lane.
Determination of Kd Values
Peptides containing a nicotinic acid substituent at their N terminus
are highly fluorescent and exhibit little or no change in fluorescence
upon coordination to the Fyn-SH3 domain. Therefore, the KD values
for the SH3 complexes of these species were determined via equi-
librium dialysis. All samples were prepared in buffer containing TBS
and 1 mM DTT at pH 7.5. A Slide-A-Lyzer dialysis slide cassette
(0.1–0.5 ml capacity) was employed and contained 30 nM or 500
nM Fyn-SH3 GST fusion proteins. The cassettes (400 l final vol-
ume) were placed in a beaker containing a volume of buffer solu-
tion (TBS and 1 mM DTT [pH 7.5]) that was at least 400-fold greater
than that of the sample volume in the dialysis cassette. As a conse-
quence, concentrations of non-SH3 bound peptide were held con-
stant in the dialysis slide cassette over the course of the experi-
ment. Equilibrium dialysis experiments were performed over a
period of at least 16 hr and were maintained at 4°C. Differences in
the fluorescence between the solution in the slide cassette and
that in the beaker were measured. The excitation wavelengths em-
ployed for the peptides were 328 nm. Emission was monitored at
378 nm. The Kd values were calculated from the following equation
for fluorescent peptides 8a, 11a, 14, and 7, where [E] = total en-t
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912zyme concentration, [E · L] = enzyme-peptide complex, and [L] =
free peptide concentration.
Kd =
{[E]t− [E ⋅ L]}[L]
[E ⋅ L]
For nonfluorescent peptide 9, the following equation was used
for the determination of Kd#:
Kd =
Kd ⋅ [L′]
[E]t⋅[L]
[E⋅L]
− (Kd + [L])
where Kd = the dissociation constant of competition fluorescent
peptide, [L#] = total nonfluorescent peptide concentration, [L] = to-
tal competitive fluorescent peptide concentration, [E]t = total SH3
domain concentration, [E · L] = enzyme-peptide (fluorescent com-
petitive peptide) complex concentration.
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